Pliant Therapeutics Under Investigation for Securities Violations
The Schall Law Firm, known for its focus on shareholder rights, is looking into potential claims for investors of Pliant Therapeutics, Inc. (“Pliant” or “the Company”) PLRX. This investigation is centered on possible violations of securities laws.
Allegations of Misleading Information
Investigators are examining whether Pliant made false or misleading statements, or failed to reveal important information to investors. On February 7, 2025, the company announced that it would pause enrollment and dosing in the BEACON-IPF Phase 2b trial of its drug bexotegrast, following a data review from the independent Data Safety Monitoring Board (DSMB). As a result, Pliant’s stock dropped by an alarming 60.59% on February 10, 2025.
Shareholders who experienced losses are encouraged to participate in this investigation.
Brian Schall from the Schall Law Firm can be reached at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by calling 310-301-3335 for a free discussion about your rights. Interested parties can also contact the firm via their website at www.schallfirm.com, or email at bschall@schallfirm.com.
The Schall Law Firm: A Leader in Investor Advocacy
The Schall Law Firm has a global reach and specializes in cases involving securities class action lawsuits and protections for shareholder rights.
Please note, this press release may qualify as Attorney Advertising in certain jurisdictions under applicable law and ethical guidelines.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20250218220073/en/
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
Market News and Data brought to you by Benzinga APIs
